{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"10.8","value":"8.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Time to disease progression is defined as the time from registration to the earlier of documentation of disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The distribution of time to progression will be estimated using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1 (6/6 UGT1A1 genotype):\n\n\\> Patients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 100 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 1600 mg/m\\^2/day capecitabine PO BID on days 2-15\n\n\\>\n\n\\>\n\nGroup 2 (6/7 UGT1A1 genotype):\n\n\\> Patients receive 150 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15.\n\n\\>\n\n\\>\n\nGroup 3 (7/7 UGT1A1 genotype):\n\n\\> Patients receive 75 mg/m\\^2 irinotecan hydrochloride IV over 90 minutes and 85 mg/m\\^2 oxaliplatin IV over 2 hours on day 1. Patients also receive 400 mg/m\\^2/day capecitabine PO BID on days 2-15","id":"OG000","title":"All Patients (6/6, 6/7, 7/7 UGT1A1 Genotype)"}],"paramType":"MEDIAN","populationDescription":"One patient was later found to be a major treatment violation during cycle 1 and was not included in this analysis. All the other 32 patients were analyzed together for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}